OKYO Pharma Limited

NasdaqCM OKYO

OKYO Pharma Limited EPS (Diluted) for the year ending March 31, 2024: USD -0.00

OKYO Pharma Limited EPS (Diluted) is USD -0.00 for the year ending March 31, 2024, a 99.90% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

OKYO Pharma Limited EPS (Diluted) for the year ending March 31, 2023 was USD -0.60, a -10,809.09% change year over year.
OKYO Pharma Limited EPS (Diluted) for the year ending March 31, 2022 was USD -0.01.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqCM: OKYO

OKYO Pharma Limited

CEO	Dr. Gary S. Jacob Ph.D.
IPO Date	May 17, 2022
Location	United Kingdom
Headquarters	55 Park Lane
Employees	8
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Eyewear

Description

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years